Relmada Therapeutics (RLMD) Non Operating Investment Income (2020 - 2026)
Relmada Therapeutics' (RLMD) quarterly Non Operating Investment Income came in at -$9867.0 in Q1 2026, down 115.67% year-on-year from $62952.0 in Q1 2025, and down 102.67% on a QoQ basis from $369538.0 in Q4 2025.
Relmada Therapeutics (RLMD) Non Operating Investment Income (2020 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 7 years of Non Operating Investment Income data on file, last reported at -$9867.0 in Q1 2026.
- On a quarterly basis, Non Operating Investment Income fell 115.67% year-over-year to -$9867.0 in Q1 2026; TTM through Mar 2026 was $264436.0, a 336.64% increase from a year earlier, with the FY2025 full-year figure at $398255.0, up 5813.21% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$9867.0, down from $369538.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for RLMD reached as high as $1.3 million in Q1 2023 and fell as low as -$3.3 million in Q4 2023.
- Historically, Non Operating Investment Income has averaged -$286858.1 across 5 years, with a median of -$33351.0 in 2022.
- Across the five-year window, Non Operating Investment Income plunged 9932.59% in 2023 and jumped 385.87% in 2024, its largest moves.
- Year by year, Non Operating Investment Income stood at -$33351.0 in 2022, then plunged by 9932.59% to -$3.3 million in 2023, then jumped by 91.72% to -$277068.0 in 2024, then soared by 233.37% to $369538.0 in 2025, then sank by 102.67% to -$9867.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were -$9867.0 in Q1 2026, $369538.0 in Q4 2025, and -$81438.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Relmada Therapeutics | 452.90 Mn | 452.90 Mn | - | -9,867.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,867.00 |
| Mar 31, 2026 | -9,867.00 |
| Dec 31, 2025 | 369,538.00 |
| Dec 31, 2025 | 369,538.00 |
| Sep 30, 2025 | -81,438.00 |
| Sep 30, 2025 | -81,438.00 |
| Jun 30, 2025 | -13,797.00 |
| Jun 30, 2025 | -13,797.00 |
| Mar 31, 2025 | 62,952.00 |
| Mar 31, 2025 | 62,952.00 |
| Dec 31, 2024 | -277,068.00 |
| Dec 31, 2024 | -277,068.00 |
| Sep 30, 2024 | 147,835.00 |
| Sep 30, 2024 | 147,835.00 |
| Jun 30, 2024 | -45,465.00 |
| Jun 30, 2024 | -45,465.00 |
| Mar 31, 2024 | 50,713.00 |
| Mar 31, 2024 | 50,713.00 |
| Dec 31, 2023 | -3.35 Mn |
| Dec 31, 2023 | -3.35 Mn |